Latest Pharma and Biotech News
Pharmaceutical
13 November 2025 Swiss pharma giant Novartis has announced positive results from KALUMA, a Phase III study for new malaria treatment KLU156 (ganaplacide/lumefantrine, or GanLum).
Today's issue
Refine Search
Pharmaceutical
The European Medicines Agency’s EMA’s human medicines committee (CHMP) recommended seven novel medicines for approval at its November 2025 meeting. 15 November 2025
Pharmaceutical
Between the US government shutdown, crippling international tariffs, debilitating funding cuts to critical research, and the general policy whiplash in Washington DC, it's little wonder many US-based life sciences companies are opting to expand in a more stable environment. Basel Area Business & Innovation says the Basel area in Switzerland is poised to welcome them. 15 November 2025
Pharmaceutical
US pharma major Bristol Myers Squibb - in collaboration with Johnson & Johnson - has announced the decision to stop the Phase III Librexia ACS trial evaluating the efficacy and safety of milvexian when added to the standard of care, of conventional antiplatelet therapy, for patients after a recent acute coronary syndrome (ACS) event. 14 November 2025
Pharmaceutical
TandemAI has announced that it has secured a $22 million Series A extension to further develop its drug discovery platform, which combines advanced AI, physics-based computational methods, and wet lab capabilities. 14 November 2025
Biotechnology
US medtech firm Terumo Blood and Cell Technologies has appointed Liza Loidolt as general manager of its cell and gene therapy business, marking a sharper strategic push into advanced therapeutics. Parent company Terumo Corporation recently reported annual revenue of about $6.1 billion, with growth in blood-and-cell technologies. 14 November 2025
Biotechnology
Chinese biotech Biokin Pharmaceutical has postponed its planned Hong Kong share listing, citing prevailing market conditions as analysts point to cooling risk appetite late in the year. 14 November 2025
Pharmaceutical
The race to find a new treatment for hair loss hotted up last month with two mega funding rounds for Pelage Pharmaceuticals and Veradermics. The deals also demonstrated biopharma’s growing interest in consumer-focused prescription products. 14 November 2025
Pharmaceutical
Merck & Co has struck a $9.2 billion deal to acquire biotechnology company Cidara Therapeutics in a move that bolsters the US pharma giant’s respiratory portfolio and pipeline as it braces for the 2028 loss of patent exclusivity for its mega blockbuster cancer drug Keytruda (pembrolizumab). 14 November 2025
Pharmaceutical
Ireland-based Avadel Pharmaceuticals today announced that it has received an unsolicited proposal from Denmark’s Lundbeck to acquire Avadel, whose shares shot up 21.7% to $19.24 in pre-market activity. 14 November 2025
Biotechnology
Mersana Therapeutics, a US biopharma developing antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, is to be acquired by Day One Biopharmaceuticals. 14 November 2025
Biotechnology
UK-based life sciences venture capital firm Medicxi today announced the closing of Medicxi V, a 500 million-euros ($579.5 million) fund dedicated to building and backing innovative European biotechnology companies with clear product visions to transform patient care. 14 November 2025
Pharmaceutical
Neurvati Neurosciences, the neuroscience development platform of Blackstone Life Sciences, has announced the appointment of Carlos Martin as chief commercial officer (CCO). 14 November 2025
Pharmaceutical
Gate Bioscience has raised $65 million in an oversubscribed series B to advance its first molecular gate candidates, a novel class of oral small molecules designed to eliminate disease-driving proteins before they are secreted. The round was led by Netherlands-based Forbion, with new backing from US pharma major Eli Lilly (NYSE: LLY). 14 November 2025
Pharmaceutical
The pharma trade group the Association of the British Pharmaceutical Industry (ABPI) and the UK government have agreed to a further extension to the deadline by which companies must give notice if they intend to leave the 2024 voluntary scheme for branded medicines pricing, access and growth (VPAG). 14 November 2025
Pharmaceutical
The US Food and Drug Administration approved USA-based Kura Oncology and Japan’s Kyowa Kirin’s ziftomenib (trade name Komzifti), a menin inhibitor, for adults with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation who have no satisfactory alternative treatment options. 14 November 2025
Biotechnology
Danish CNS company Lundbeck has had its new drug application for Vyepti (eptinezumab) accepted by Japan’s health ministry, marking a major step toward expanding its presence in Asia. 14 November 2025
Generics
German generics and consumer healthcare major STADA Arzneimittel has appointed Craig Shaw as its general manager in the UK. 14 November 2025
Biotechnology
Sino-American antibody company Adagene and Third Arc Bio today announced a licensing agreement under which Third Arc Bio will utilize Adagene’s SAFEbody technology platform to generate masked CD3 T cell engagers against unique tumor associated antigens. 13 November 2025
Pharmaceutical
Swiss clinical-stage biotech, which is pioneering fully synthetic vaccines, today announced the completion of a $15 million financing round from existing shareholders. 13 November 2025
Pharmaceutical
German radiopharma company ITM Isotope Technologies Munich SE (ITM) has announced that the US Food and Drug Administration (FDA) has completed its filing review and accepted the company’s New Drug Application (NDA) for n.c.a. 177Lu-edotreotide—also known as ITM-11. 13 November 2025
All news
Biotechnology
Shares of US clinical stage biopharma Candel Therapeutic closed down 10.4% at $5.78 on Tuesday after it revealed it has entered into a five-year, $130 million term loan facility with Trinity Capital. 15 October 2025
Pharmaceutical
If recent top-line reads deliver on the big stage, this week's ESMO 2025 could re-draw standards across breast, genitourinary, gynaecologic and colorectal cancers—powered by three recurring themes: ADCs stepping earlier, radioligand therapy moving upstream and immuno-oncology showing life beyond metastatic niches. 14 October 2025
Pharmaceutical
Aurélie-Anne Chausse has joined the Kyowa Kirin International (KKI) unit of Japanese drugmaker Kyowa Kirin in the France and Benelux-focused role of general manager, central cluster. 14 October 2025
Biotechnology
North Carolina, USA-based biotech BioCryst Pharmaceuticals today announced that it has entered into a definitive agreement to acquired Astria Therapeutics, a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases. 14 October 2025
Pharmaceutical
USA-based Kailera Therapeutics, which is focused on next-generation therapies for the treatment of obesity, today announced a $600 million Series B financing led by new investor Bain Capital Private Equity. 14 October 2025
Pharmaceutical
US healthcare giant Johnson & Johnson has announced its third-quarter financial results and guidance for the rest of 2025. 14 October 2025
Pharmaceutical
The new Innovative Licensing and Access Pathway (ILAP) of the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has welcomed its first investigatio76i67-nal products. 14 October 2025
Biotechnology
Cambridge, USA-based generative protein design pioneer Nabla Bio today announced a new, multi-year research collaboration with Japanese pharma major Takeda. 14 October 2025
Biotechnology
Shares in US biopharma Scholar Rock closed 13% lower Monday after bad news on its spinal muscular atrophy (SMA) treatment apitegromab. 14 October 2025
Biotechnology
China’s out-licensing deals have significantly increased over the last five years, showcasing the country as a source of innovative drugs. The licensing agreements provide global recognition as well as validation for China’s advancements in drug development. 14 October 2025
Biotechnology
Texas, USA-based fibrosis drug developer Tvardi Therapeutics shares plunged 84% on Monday to $6.59, erasing much of its previous 128% six-month gain, following disappointing Phase IIa clinical trial results for its TTI-101 drug in idiopathic pulmonary fibrosis (IPF). 14 October 2025
Biotechnology
Boston, USA-based Bicara Therapeutics, a biotech focused on developing bifunctional therapies for solid tumors, announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) for. its ficerafusp alfa in combination with Merck & Co’s Keytruda (pembrolizumab). 14 October 2025
Generics
German active pharmaceutical ingredients company Medac, specializing in therapeutic solutions for oncology, rheumatology, urology and hematology, today announced the acquisition of Biotech Pharma, based in Dubai. 14 October 2025
Pharmaceutical
French biotech EVerZom has raised 10 million euros ($10.9 million) to launch its first clinical trial and expand its exosome platform into new areas such as liver and skin disease. The financing round attracted support from Capital Grand Est, the European Innovation Council Fund, Sorbonne Venture, Aloe Private Equity, Paris Business Angels, Capital Cell and several family offices. 14 October 2025
Pharmaceutical
The United Kingdom has long cast itself as a global leader in research and innovation, and government ministers still speak of a future in which the country stands tall as a science superpower. 14 October 2025
Pharmaceutical
Belgium’s largest drugmaker UCB has announced the final analysis of an open-label extension (OLE) study on Fintepla (fenfluramine) in Lennox-Gastaut syndrome (LGS), which was published in Epilepsy and Behavior. 14 October 2025
Generics
In what is being termed a major victory, Natco Pharma has won a legal battle against Swiss pharma giant Roche, allowing the launch of generic Evrysdi (risdiplam) for spinal muscular atrophy (SMA) treatment in India, at a cost which is 97% cheaper. 14 October 2025
Pharmaceutical
German pharma major Boehringer Ingelheim has appointed Vani Manja as senior vice president and global head of its newly formed obesity and liver health unit. The move signals Boehringer’s determination to capture share in two of the fastest-growing therapeutic areas worldwide. 14 October 2025
Biotechnology
US biotech Arcus Biosciences and partner Gilead Sciences have unveiled encouraging survival data for domvanalimab in gastric cancer, with new results presented in a mini oral session at the ESMO 2025 Congress. 14 October 2025
Pharmaceutical
Across the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) pushed two pace-setting moves: trial approval times are now halved to 41 days thanks to AI-supported and risk-proportionate reforms; and, six months early, MHRA with the National Institute for Health and Care Excellence (NICE) opened “aligned pathway” early-adopter slots so licensing and value decisions can publish together. 13 October 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze